Long-term outcome of an intravitreal dexamethasone implant for the treatment of noninfectious uveitic macular edema

Ophthalmologica

Volumn 232, Issue 2, 2014, Pages 77-82

  Habot Wilner, Zohar ^a   Sorkin, Nir ^a   Goldenberg, Dafna ^a   Loewenstein, Anat ^a   Goldstein, Michaella ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cystoid macular edema; Dexamethasone intravitreal implant; Ozurdex; Spectral domain optical coherence tomography; Uveitic macular edema; Uveitis

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; ARTICLE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG DELIVERY SYSTEM; DRUG IMPLANT; FEMALE; FOLLOW UP; FUNDUS CAMERA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LONG TERM CARE; MALE; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PHASE 2 CLINICAL TRIAL (TOPIC); RETINA MACULA CYSTOID EDEMA; RETINAL THICKNESS; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUSTAINED DRUG RELEASE; UVEITIC MACULA EDEMA; UVEITIS; VISUAL ACUITY; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VITREOUS BODY; YOUNG ADULT;

ADULT; DEXAMETHASONE; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VITREOUS BODY; YOUNG ADULT;

EID: 84925284405     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000362178     Document Type: Article

References (23)

1. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A: Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996; 80: 332-336.
2. Suttorp-Schulten MS, Rothova A: The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996; 80: 844-848.
3. Lardenoye CW, van Kooij B, Rothova A: Impact of macular edema on visual acuity in uveitis. Ophthalmology 2006; 113: 1446-1449.
4. Kiss CG, Barisani-Asenbauer T, Maca S, Richter-Mueksch S, Radner W: Reading performance of patients with uveitis associated cystoid macular edema. Am J Ophthalmol 2006; 142: 620-624.
5. McDonough AK, Curtis JR, Saag KG: The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008; 20: 131-137.
6. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J: Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001; 108: 765-772.
7. Kok H, Lau C, Maycock N, McCluskey P, Lightman S: Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005; 112: 1916-1921.
8. Angunawela RI, Heatley CJ, Williamson TH, Spalton DJ, Graham EM, Antcliffe RJ, Stanford MR: Intravitreal triamcinolone acetonide for refractory uveitic cystoid macular oedema: long-term management and outcome. Acta Ophthalmol Scand 2005; 83: 595-599.
9. Morrison VL, Kozak I, LaBree LD, Azen SP, Kayicioglu OO, Freeman WR: Intravitreal triamcinolone acetonide for the treatment of immune recovery uveitis macular edema. Ophthalmology 2007; 114: 334-339.
10. Baath J, Ells AL, Crichton A, Kherani A, Williams RG: Safety profile of intravitreal triamcinolone acetonide. J Ocul Pharmacol Ther 2007; 23: 304-310.
11. Maca SM, Abela-Formanek C, Kiss CG, Sacu SG, Benesch T, Barisani-Asenbauer T: Intravitreal triamcinolone for persistent cystoid macular oedema in eyes with quiescent uveitis. Clin Experiment Ophthalmol 2009; 37: 389-396.
12. Habot-Wilner Z, Sallam A, Pacheco PA, Do HH, McCluskey P, Lightman S: Intravitreal triamcinolone acetonide as adjunctive treatment with systemic therapy for uveitic macular edema. Eur J Ophthalmol 2011; 21: 56-61.
13. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group: Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125: 309-317.
14. Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group: Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009; 147: 1048-1054.
15. Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM; Ozurdex HURON Study Group: Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129: 545-553.
16. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T; Fluocinolone Acetonide Uveitis Study Group: Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty four-week results of a multicenter randomized clinical study. Ophthalmology 2006; 113: 1020-1027.
17. Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL: Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008; 126: 1191-1201.
18. Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW; Fluocinolone Acetonide Study Group: Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010; 117: 567-575.
19. Arcinue CA, Cerón OM, Foster CS: A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther 2013; 29: 501-507.
20. Myung JS, Aaker GD, Kiss S: Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant. Clin Ophthalmol 2010; 4: 1423-1426.
21. Miserocchi E, Modorati G, Pastore MR, Bandello F: Dexamethasone intravitreal implant: an effective adjunctive treatment for recalcitrant noninfectious uveitis. Ophthalmologica 2012; 228: 229-233.
22. Adán A, Pelegrín L, Rey A, Llorenç V, Mesquida M, Molins B, Ríos J, Keller J: Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina 2013; 33: 1435-1440.
23. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group: Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 2005; 140: 509-516.